Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CigArrest is a consumer healthcare company specializing in smoking cessation products and programs. The company's primary offering is a multi-component system designed to help individuals quit smoking through a combination of homeopathic tablets, gum, and behavioral support materials. Its products typically feature lobeline, a botanical alkaloid derived from the Lobelia inflata plant, which is intended to mimic the effects of nicotine on the nervous system to reduce cravings. CigArrest has been a prominent name in the over-the-counter smoking cessation market for several decades, often marketed through direct-to-consumer channels and retail pharmacies. The program emphasizes a natural approach to overcoming nicotine addiction without the use of nicotine replacement therapy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CigArrest.